Cytosolic Delivery of Thiolated Neoantigen Nano‐Vaccine Combined with Immune Checkpoint Blockade to Boost Anti‐Cancer T Cell Immunity
Abstract Although tumor‐specific neoantigen‐based cancer vaccines hold tremendous potential, it still faces low cross‐presentation associated with severe degradation via endocytosis pathway. Herein, a thiolated nano‐vaccine allowing direct cytosolic delivery of neoantigen and Toll like receptor 9 ag...
Main Authors: | Da Zhang, Ziguo Lin, Ming Wu, Zhixiong Cai, Youshi Zheng, Lei He, Zhenli Li, Jie Zhou, Liqin Sun, Geng Chen, Yongyi Zeng, Juan Li, Jingfeng Liu, Huanghao Yang, Xiaolong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Advanced Science |
Subjects: | |
Online Access: | https://doi.org/10.1002/advs.202003504 |
Similar Items
-
NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma
by: Xingxing Jian, et al.
Published: (2022-09-01) -
The tRNA thiolation-mediated translational control is essential for plant immunity
by: Xueao Zheng, et al.
Published: (2024-01-01) -
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
by: Xue-lin Zou, et al.
Published: (2021-12-01) -
Current Trends in Neoantigen-Based Cancer Vaccines
by: Szu-Ying Ho, et al.
Published: (2023-03-01) -
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
by: David Repáraz, et al.
Published: (2022-02-01)